Polaris-AD: AR1001 Additional Phase 2 Data And Phase 3 Trial Update With Topline Results Expected Later This Year

mirodenafil (AR1001) - ariBio, Samjin Pharma

Niels Prins1; Alireza Atri2; SangYun Kim, M.D.,Ph.D.3; Yi Tang4,5; David Greeley6; James A. Rock7; Fred Kim7; Jai Jun Choung4,7; Sharon J. Sha4,8.

Jun 30, 2026